Expert Describes How Robotic Device Streamlines Cancer Surgical Process

Commentary
Video

The Epione robot eliminates the need for multiple check scans during surgery by allowing physicians to target a tumor with a single button press, according to Govindarajan Narayanan, MD.

CancerNetwork® spoke with Govindarajan Narayanan, MD, about how Epione, a robotic tool, streamlines ablative surgical procedures for cancer by minimizing the need for certain manual corrections when administering the needle to a patient’s tumor.

Narayanan, a professor of Radiology and an interventional radiologist at Miami Cardiac and Vascular Institute and the chief of Interventional Oncology at Miami Cancer Institute, both of Baptist Health South Florida, highlighted his methodology prior to the advent of the Epione robot, which involved using CT scans as guidance for manually adjusting the needle’s precision in the middle of ablative surgery. He indicated that planning and executing the procedure becomes simplified with Epione, as a single button press allows physicians to push the needle towards the targeted tumor, thereby reducing patient and operator exposure to radiation that they may experience during standard check scans.

Transcript:

The Epione robot is something that helps us with ablations or needle-based procedures that we do. When we do ablations, we typically use CT scan guidance or ultrasound. As interventional radiologists, we are trained to advance the needles in different planes. You go from the skin to the target, making adjustments to your needle along the way. To go from the skin to the target, you have to plan it; as you go in with the needle, you need to make adjustments. The needle could be a little towards the head or to the feet, or anterior or posterior.

You have to make all those adjustments as you’re doing it. Before Epione, all of this had to be done in your head, and you had to manually make the adjustments. With the Epione robotics system, you plan everything in the workstation of the robot. Once it has plotted the path for you, you can pretty much push the needle from the skin to the target with one push instead of having to do multiple check scans, which involves radiation to the patient and to the operator.

Reference

Epione. Quantum Surgical. Accessed November 7, 2023. https://shorturl.at/dqyL6

Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Related Content